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Peritoneal dialysis (PD) as a renal replacement therapy (RRT) has become wide spread since its inception more than twenty-
ﬁve years back. Since then, several advances have been made and PD has been accepted as an alternative therapy to hemodialysis
(HD),withexcellentsurvival,lowercost,andimprovedqualityoflife.InspiteofcomparablesurvivalofHDandPD,improvedPD
techniquesoverthelastfewyears,andlowerhealthcarecostswithPD,PDprevalenceremainslowinmanycountries.Animportant
reason for the low PD prevalence is patient dropouts, that is, transfer to HD. The reasons for dropouts are multifactorial, that is,
modalityrelated,systemrelated,andpatientrelated.Theseincludeepisodesofperitonitis,catheter-relatedproblems,ultraﬁltration
failure, patient fatigue, and provider comfort. This review discusses the various factors that contribute to PD dropout and the
strategies to prevent it.
1.Introduction
Peritoneal dialysis (PD) has been in use for the last thirty
years for treatment of end-stage renal disease but barring a
few countries the prevalence of PD is lower than Hemodial-
ysis (HD). For example as per USRDS data from 2007, of
approximately 368,000 patients undergoing dialysis in the
United States (USA), the point prevalence for PD patients
was only 7.2% [1]. Contrary to prevailing practice, a survey
of nephrology professionals found that the majority picked
CAPD/APD as the best initial therapy for the patient [2]. Of
theoneswhoperformPD,fewpatientsstayonPDfor5years
or longer from initiation of therapy. A large proportion of
such patients transfer from PD to HD every year, and PD
to HD switch rates of more than 35% have been reported
[3, 4]. Thus transfer to HD is a signiﬁcant cause for the low
prevalence of PD. The risk of transfer to HD is the highest in
the ﬁrst few months of PD initiation, mainly due to episodes
of peritonitis and catheter-related problems and decreases
thereafter [5]. Modality issues such as recurrent episodes
of peritonitis, inadequate dialysis or ultraﬁltration failure,
systemissuessuchaslackofinfrastructureaswellaspersonal
or social reasons make up the bulk of causes for transfer
to HD (Table 1). Peritonitis and inadequate dialysis issues
have received great attention and despite the incidences
havingdecreasedthelastfewyears,PDdrop-outstillremains
widespread. Strategies to prevent and manage peritonitis,
ultraﬁltration failure, catheter-related complications, and
improving adequacy of dialysis, education of patients, and
medical staﬀ may all help with maintaining the patient on
PD (Table 2).
2. Reasons for PD Drop-out
2.1. Modality-Related Issues
2.1.1. Peritonitis and Catheter-Related Infections. Am a j o r
cause for the transfer from PD to HD is high rates of
peritonitis, especially within the ﬁrst 1 to 2 years of initiating
PD. Peritonitis episodes, even if not the approximate cause
of technique failure (TF), can cause ultraﬁltration failure
(UF) and membrane-related problems at a later time. The
use of twin bags and Y set system has helped decrease
the peritonitis rates signiﬁcantly in the last few years [6].2 International Journal of Nephrology
Table 1: Potential causes of transfer to HD.
Modality related
Peritonitis
Tunnel infection, exit site infections
Inadequate dialysis
Ultraﬁltration failure
Catheter malfunction
System related
Lack of patient education/training
Transfer to a facility where PD is unavailable
Center eﬀect
Provider expertise
Ownership of dialysis facility
Patient related
Patient fatigue/burnout
Social reasons, family, occupation, and so forth
Geography: distance to travel
Loss of RRF
Malnutrition and/or excess protein loss
Abdominal surgeries/hernia
Stroke or severe illness, limiting the manual dexterity
Data from Canadian Organ Replacement Registry (CORR)
from 1981 to 1997 estimated the crude CAPD switch rates
to be 154/1000patient-year. Compared to earlier years, the
adjusted relative risk of CAPD failure ranged from 0.75
to 0.83 for the years 1990 and onwards [7]. In another
prospective study of 292 PD patients involving 28 dialysis
centers, 24.8% PD patients switched to HD during the
study period and 40% of those patients switched within
the ﬁrst year and 70% within two years of starting PD [8].
In their series, the most common cause for the switch was
infection related (both peritonitis and catheter related) at
36.9% followed by volume overload at 18.5%. Peritonitis
rates in randomized trials using double bag systems have
shown an incidence rate of peritonitis ranging from one
episode per 24.8 months to one episode per 46.4 months
[9]. In a study of peritonitis rates in 12PD units in the
United Kingdom (UK), the author reported peritonitis
rates of one episode per 14.7 months for CAPD and one
episode per 18.1 month for APD/CCPD patients, with a
considerable variation between units [10]. Catheter-related
interventions, including changes in design and approach
have been tried in an eﬀort to reduce peritonitis rates. In
a review of 37 trials including 2822 patients Strippoli et
al. did not ﬁnd statistical diﬀerence in peritonitis rates,
or technique failure with catheters inserted by laparoscopy
versuslaparotomyorbetweencatheterswithastraightversus
coiled intraperitoneal portion [6]. In a comparison of pre-
sternal versus intraperitoneal PD catheters, Twardowski et al.
foundthatthe peritonitis rate was1episode per37.4patient-
months and 1 per 20.5 patient-months for presternal and
abdominal catheters, respectively, but these diﬀerences were
not statistically signiﬁcant. However, the patients receiving
the presternal catheters included obese patients (5 patients
with BMI > 45), and 3 patients had ostomies [11].
Table 2: Strategies to prevent PD drop-out.
Modality related
Peritonitis prophylaxis and treatment
Membrane preservation: Use of Glucose polymers/ACE inhibitors
Adjust dialysis prescription according to RRF
Correction of catheter malfunction
System related
Better infrastructure to support PD
Patient education/training
Physician and nursing education
Larger PD centers
Patient related
Social support
Psychological counseling (as needed)
Assisted PD
2.1.2. Ultraﬁltration Failure and Volume Overload. Inability
to maintain adequate volume status is another cause of fail-
ure of PD as a modality. This could be due to several reasons
including ultraﬁltration failure, decline in RRF, or excessive
salt and water intake. The diagnosis of true ultraﬁltration
failureasperISPDguidelinescanbeascertainedusing4.25%
dextrose solution for 4 hours and getting >400mL of net
ultraﬁltration [12] .T h ep r e v a l e n c eo fu l t r a ﬁ l t r a t i o nf a i l u r e
as a cause of TF has been reported to be between 1.7%
and 13.7% [13]. A study of PD cohort followed in the
Netherlands had a high rate of technique failure, with only
64% of patients remaining on PD after 2 years [14]. The
factors identiﬁed as independent predictors for this were
urine volume, systolic blood pressure, and peritoneal ultra-
ﬁltration. In a study from Japan, the authors reported that
failureofultraﬁltrationwasthebiggestreasonforwithdrawal
from CAPD in patients staying on PD for greater than 6
years [15]. In both these studies the major modality was
CAPD and Icodextrin was not used. However, recent studies
have shown that cohorts of incident PD patients starting
dialysis from 2002 onwards had lower rates of transfer to
PD as compared to cohorts from earlier years [16, 17].
Long-term exposure to hypertonic glucose solutions changes
the transport characteristics of peritoneal membrane. Low
or average transporters become high transporters and may
lead to a greater use of high-strength dextrose solutions.
The resulting volume expansion is often compounded over
time as the residual renal function (RRF) declines over
time as well. Volume overload may be due to causes
besides peritoneal membrane dysfunction. Dietary indis-
cretion, excessive sodium, and ﬂuid intake; an inadequate
dialysis prescription; loss of residual renal function without
adjustments in dialysis prescription; catheter malfunction
often are the cause of inadequate volume control.
2.1.3. Catheter Malfunction. Mechanical complications of
PD catheters are another reason for failure of PD and
transfer to HD. Migration of catheters and blockage due to
omental trapping are frequent causes of malfunction. EarlyInternational Journal of Nephrology 3
and appropriate intervention can save many catheters, often
without interrupting PD [18].
2.2. System-Related Issues. Compared to some countries
such as Canada or UK, where accessibility to HD can be
limited, HD is more readily available in the USA [19]. Thus,
prevalence of PD is higher (20%–30%) in Australia, New
Zealand, China, Canada, and the UK, where PD delivery is
supported and provided for by the government [20, 21]. In
Hong Kong, where 80% of the dialysis population is on PD
(HD is only permitted if there is a contraindication to PD)
a 2-year technique survival of 82% (patient survival 91%)
has been reported [22]. Besides reimbursement policies and
possible genetic eﬀects [23] the success of PD in Hong
Kong is due to the high numbers of PD patients each
unit has, that is, around 300, increasing the staﬀ expertise.
For example the training duration for PD is only 4-5
days, and many procedures such as catheter insertion and
removal are performed by nephrologists, decreasing surgical
consultations, and providing timely treatment.
In a recent study, during the 9-year period between
1996 and 2004, the number of units owned by large dialysis
organizations (LDOs) in the USA increased by >50% [24].
The number of patients undergoing dialysis in these units
increased from 39% to 63% with no increase in number of
patients undergoing PD. Three of the ﬁve LDOs in the above
study had consistently lower peritoneal dialysis patients and
higherriskofdeathinthosepatientsthantheotherLDOand
non-LDO owned units. It has been reported that the drop-
out rates are higher in centers having fewer number of PD
patients, generally <20–25 [3, 4, 25]. Studies have linked the
low number of peritoneal dialysis patients in a center to high
technique failure and low patient survival [26, 27]. Thus a
vicious cycle can develop where low numbers of peritoneal
dialysis patients lead to lack of training/expertise [25–28],
whichinturnaﬀectstheabilitytoproblemsolveinthefaceof
technique failure leading to patient drop-out. In a Program
Director survey, 29% of US training programs had less
than ﬁve chronic peritoneal dialysis patients per nephrology
trainee. Similarly, in 14% of US training programs, fellows
spent less than 5% of their time receiving training for
patientsundergoingchronicperitonealdialysisandonly32%
ofrenalfellowsstatedthattheyattendedoutpatientPDclinic
[29]. Inadequate training in the modality may lead to a lack
of comfort with the therapy and nephrologists who are not
comfortable with peritoneal dialysis might have a tendency
of transferring patients to HD more readily.
2.3. Patient-Related Issues. Of the several patient-related
factors which contribute to underutilization of PD, getting
inadequate predialysis education is one. There is a strong
relationship between the probabilities of oﬀering peritoneal
dialysis as a treatment option to the selection of chronic
peritoneal dialysis as a treatment modality [30]. Geography
and distance play an important role, and the distance to
travel to the dialysis unit may be a factor [31].
In a study of the Dutch registry from 1994 to 1999, the
investigators did not ﬁnd diabetes and patient’s sex related to
technique failure but advancing age was related to TF [25].
In another study, the technique failure rates were the same
with patients above and below 55 years of age. Diabetics had
a slightly higher technique failure rate, but the results did not
reach statistical signiﬁcance [4]. In a prospective study of 262
patients, Jaar et al. [8] found that 18.2% of patients switched
due to ﬂuid overload problems. Abdominal surgeries and
malnutrition were other leading causes of PD failure in the
study. Although dialysis provides life-sustaining therapy for
patients with irreversible renal failure, it does not restore a
normal quality of life. Over time a certain level of fatigue
may occur in PD patients as a result of both their disease
and of their constant requirement to perform life-sustaining
dialysis. This chronic patient burnout is another reason for
PD drop-out especially if adequate psychosocial support is
not available.
3. Prevention Strategies
3.1. Dialysis Related
3.1.1. Peritonitis. Prevention and better treatment of peri-
tonitis and catheter-related infections will undoubtedly
decrease the loss of some patients from PD. Prophylaxis
against exit site infection leads to subsequent fewer episodes
of peritonitis and both mupirocin and gentamycin are used
for this. Nasal carriage of Staphylococcus aureus has been
linked to increased rates of peritonitis [32]; screening and
prophylaxis with antibiotics has shown to decrease the rates
of peritonitis [33, 34]. Bernardini et al. [35] shows that
the use of gentamycin was more eﬀective than mupirocin
in preventing gram-negative infections and equally eﬀective
as mupirocin against gram positive organisms. In certain
centers APD has been associated with lower peritonitis and
technique failure [36], and more widespread use of APD
can oﬀset some of the patients failing PD. In the study
discussed above [10] patients receiving both cephalosporins
and a second antibiotic (i.e., gentamycin) by intraperitoneal
route had the best cure rates of 94.55%, compared to
patients receiving either intraperitoneal vancomycin or oral
cephalosporins, and dual initial coverage until the cultures
and sensitivity come back should be considered as the
standard practice. Investigating the cause for variability of
peritonitis rates from one center to another in a geograph-
ical region as well as reviewing training techniques and
center-speciﬁc protocols periodically can help minimizing
peritonitis episodes. Reduction in peritonitis rates using
biocompatible solutions has not been shown in prospec-
tive randomized controlled trials (RCT). One retrospective
study using biocompatible solutions showed lower rates of
peritonitis rates (1 episode/36 versus 1 episode/21 patient-
months), as compared to use of standard solution [37].
Another single center study of 121 cases of peritonitis also
found a lower rate of peritonitis (1 episode/52.5 versus 1
episode/26.9patient-months) in patients treated with bio-
compatible solutions as compared to standard solution [38].
However other studies including the Euro-balance study
usingbiocompatiblesolutionshavenotshownanydiﬀerence
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recommend use of biocompatible solutions as a measure for
reducing peritonitis rates.
3.1.2. Ultraﬁltration Failure/Volume Status. Glucose, the
osmotic agent in standard PD solutions, causes changes in
the membrane over time which eventually leads to mem-
brane failure [41]. Newer biocompatible solutions without
dextrose have shown evidence of less membrane damage and
mightleadtobetterpreservationoftheperitonealmembrane
[42]. In a Japanese cohort of greater than 7000 patients,
the drop-out rate of patients who used Icodextrin (8.9%),
was signiﬁcantly lower than those using dextrose (14.5%),
(P<0.0001) [43]. In a double blind randomized trial in
PD patients use of Icodextrin in long dwell versus standard
2.25% dextrose solution achieved greater ultraﬁltration and
sodium losses [44]. As the transport status of the patient
changes and low transporters become high transporters, use
of cycler can maintain the ultraﬁltration and continue the
patient on PD. Maintenance of RRF is of importance in PD
patients, and rates of decline of RRF have been associated
with all-cause mortality as well as TF [45]. The eﬀects of
newer biocompatible solutions have been studied in clinical
trials such as Euro-balance which showed a signiﬁcant
improvement in eﬄuent markers of peritoneal membrane
integrity and signiﬁcantly decreased circulating AGE lev-
els, along with better preservation of RRF but decreased
peritoneal ultraﬁltration [40]. In a 12-month randomized
study[39],nodiﬀerencewasseenforultraﬁltrationvolumes,
urine output, and RRF in patients that used neutral solution
versus standard solution. Another randomized controlled
study of 93 incident PD patients comparing standard to
biocompatible solutions did not ﬁnd a diﬀerence in RRF at 3
and12months[46].Theuseofbiocompatiblesolutionswith
lower levels of glucose degradation products (GDPs) may
preserve the RRF longer, although this eﬀect may be volume
related [47]. Often the PD patient’s prescription does not get
changedtocompensateforthelossinRRF.Closeattentionto
the prescription and to protecting the peritoneal membrane
as well as patient education about diet and maintenance
of dry weight and use of loop diuretic are essential in
achieving normovolemia in PD patients. To maintain RRF,
nephrotoxic agents such as contrast and aminoglycoside
(AG) should be avoided as far as possible and used only
as a short course with drug level monitoring. The dialysis
prescription should be optimized to avoid dehydration and
hypotension which can adversely aﬀect the RRF. Since HD
has been associated with an increased rate of loss of RRF
as compared to PD [48, 49], temporary HD at dialysis
initiation which may reduce the RRF should be avoided
if possible [50]. The renoprotective eﬀects of inhibitors of
renin angiotensin system (RAS) may also apply to dialysis
patients in preserving the RRF and improve outcomes. Two
RCTs using ramipril and valsartan, respectively, have shown
that in select populations their use was associated with
preservation of RRF, but patients in whom these drugs
could not be withdrawn were excluded from the study [51,
52]. In another study of incident PD patients, where there
was no exclusion based on cardiovascular status, Kolesnyk
et al. showed no decline in RRF over a 3-year period [53].
The same investigators showed that use of RAS inhibitor
led to less increase in small solute transport as compared
to controls [54], which may have a positive impact on PD
survival. Newer solutions using a combination of crystalloid
and colloid as well as low sodium solutions are being
investigatedinaneﬀorttoimproveﬂuidandsodiumremoval
[55, 56].
3.1.3. Catheter Issues. Many causes of catheter malfunction,
such as occlusion by bladder or bowels, can be corrected
with the use of laxatives or emptying the bladder. Clots
can be dislodged by injecting heparinized saline and if
unsuccessful, by instillation of tPA or urokinase in the
catheter. Common mechanical problems of omental trap-
ping, adhesion formation, and so forth, can be corrected
through laparoscopic means by performing omentopexy,
adhesiolysis, resection of epiploic appendices, colopexy, and
soforth,[57].Radiologicalimagingshouldbedoneearlyand
judiciously to get a better idea of the underlying problem,
such as migrated catheters, which can also be successfully
corrected by laparoscopic approach. The use of presternal
catheters can allow certain type of patients, that is, obese, or
ones having a colostomy an opportunity to do PD.
3.2. System Related
3.2.1. Optimizing the PD Facility. Successful PD programs
are usually of a size that allows nurses to assume primary
responsibility for patient care. Optimal ratios of nurses to
patients are generally felt to be about 1:20. Nurses develop
a rapport with patients that is professionally satisfying and
they have a sense of autonomy that is particularly rewarding.
Thus, conceptually, programs of 50 or more PD patients
would seem to be optimum. Larger programs provide
ﬂexibility with nursing on-call schedules and allows nurses
time to actively participate in educational programs. The
goal of a smaller program should be to try and reach this
threshold and/or consider consolidating on a regional basis
to provide more eﬀective patient care. In certain parts of the
world, identifying a center of excellence which can establish
satellite programs has been used. One such model used in
China resulted not only in rapid growth of PD but also
had excellent technique survival of 93% at one year and
peritonitis rates of 0.26 episodes per year at risk [58].
3.2.2. Patient Education and Training. A predialysis program
where patients can be referred a few months before the need
for dialysis can go a long way towards preparing the patient
for PD and educate them regarding possible complications
[59]. Such a program should include nephrologists, nurses,
dieticians, social workers, and even other dialysis patients. In
a report from Hong Kong 50% of patients who were oﬀered
PD were reluctant to start PD, but agreed after predialysis
counseling [60]. Another report from the United kingdom
showed that close to 50% of patients who receive an expla-
nation for both PD and HD through predialysis counseling
chose PD [61]. In USA the National Pre-ESRD Education
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educators from all over the United States, is the largest pre-
ESRD program undertaken to date [62]. It enrolled 15,000
patients who were educated regarding kidney function,
kidney failure, and renal replacement therapies. The patients
chose the dialysis modality after completion of the program,
and 55% chose hemodialysis, while 45% chose peritoneal
dialysis. Along with predialysis education, eﬀective patient
PD training and retraining is important for a successful
PD program. A Training program with a well-structured
curriculum may be associated with improved outcomes [63].
PD training done at the patient’s home has been shown
to lower peritonitis rates [64]. Thus patient education and
training/retraining is a key targetformaintaining patients on
PD.
3.2.3. Physician Education and Training. To oﬀset the con-
cerns about nephrologists not being comfortable with PD,
training programs must provide fellows adequate exposure
to PD. Programs with limited access can oﬀer their trainees
elective rotations in centers with larger PD population and
have a core curriculum for PD including text and visual aids.
For example, the current RRC requirement of minimum 12
monthsofclinicalnephrologycanperhapsbeincreasedto15
or 18 months to get greater PD exposure.
3.2.4. Financial Considerations. The issues related to physi-
cian and center reimbursement are more diﬃcult to over-
come, but the introduction of bundling of services (treat-
ments, labs, and medications) of dialysis care into one
payment will help indirectly by having more patients treated
with PD. PD, where there is far less use of injectables as well
as utilization of labor, may come out ahead of HD ﬁnancially
and result in increased PD population.
3.3. Patient Related
3.3.1.PreventingPatientBurnouts. Patient“Burnout”should
be handled with counseling. Providing psychosocial support
in the form of home visits by nurses or health aides can
minimize this problem. Programs have utilized “assisted
peritoneal dialysis”—where the therapy is performed with
the assistance of either a visiting nurse or a family member
with good results especially in elderly and unplanned starts
[65]. Family support has been associated with an increase
in peritoneal dialysis eligibility from 63% to 80%, and an
increase in peritoneal dialysis utilization from 23% to 39%
among patients who had a barrier to self-care peritoneal
dialysis [66]. Assisted PD can help certain patients stay on
PD longer.
4. Conclusion
Peritoneal dialysis utilization continues to be low in many
countries. In the USA the recent bundling of services
for dialysis care into one payment oﬀe r sP Da sac o s t -
eﬀective therapy and has generated a renewed interest in the
dialysis community which can lead to improved provider
expertise and comfort and eventually greater PD utilization.
Patient drop-out contributes to the underutilization and is
multifactorial, that is, modality related, system related, and
patient related. Towards this end, both patient and physician
education and comfort with using this modality are critical.
Techniques to prevent and minimize episodes of peritonitis,
use of more biocompatible solutions in preserving the
peritoneal membrane, and careful management of volume
status can sustain the patient longer on PD. Use of drugs
suchasACEinhibitorsandARBscanpreservethemembrane
longer. Appropriate and timely radiological and surgical
interventions can prevent the malfunction and loss of PD
catheters.PsychologicalhelpaswellasassistedPDwithhome
aide can minimize the phenomenon of “burnouts”.
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